ReAlta Life Sciences, Inc.
ReAlta Life Sciences is a clinical stage biotech company dedicated to saving lives by rebalancing the inflammatory response through their EPICC technology platform. They focus on developing novel drugs with dual-targeting capabilities to modulate complement and inflammatory processes, aiming to treat rare and inflammatory diseases. Their mission emphasizes doing what is right for the patient, integrity, going beyond, fostering creative tension, and working as one team.
Industries
Nr. of Employees
small (1-50)
ReAlta Life Sciences, Inc.
Products
Lead clinical peptide candidate (dual-targeting complement and neutrophil inhibitor)
A PEGylated short peptide clinical candidate developed to inhibit classical and lectin complement initiation and neutrophil-mediated inflammatory effectors; evaluated in preclinical disease models and early human studies for biomarker-defined target engagement.
Lead clinical peptide candidate (dual-targeting complement and neutrophil inhibitor)
A PEGylated short peptide clinical candidate developed to inhibit classical and lectin complement initiation and neutrophil-mediated inflammatory effectors; evaluated in preclinical disease models and early human studies for biomarker-defined target engagement.
Services
Clinical development and translational research for peptide therapeutics
Design and conduct of early-phase clinical studies and translational programs for peptide-based anti-inflammatory candidates, including biomarker strategy and IND-enabling activities.
Preclinical efficacy and translational assay services
Preclinical program execution including in vivo efficacy studies, ex vivo human specimen testing, and biomarker assay deployment to support translation to clinical development.
Clinical development and translational research for peptide therapeutics
Design and conduct of early-phase clinical studies and translational programs for peptide-based anti-inflammatory candidates, including biomarker strategy and IND-enabling activities.
Preclinical efficacy and translational assay services
Preclinical program execution including in vivo efficacy studies, ex vivo human specimen testing, and biomarker assay deployment to support translation to clinical development.
Expertise Areas
- Peptide therapeutics
- Complement pathway modulation
- Neutrophil effector inhibition
- Preclinical animal model development
Key Technologies
- Peptide sequence optimization
- PEGylation for peptide solubility
- Sarcosine-substitution peptide chemistry
- Complement activation assays